- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
173
Fig. 9. Diffusion tensor fiber tractography of the optic radiation
optic radiation is separated from the lateral ventricle by the structure known as the tapetum. The average distance between the temporal pole and the loop of Meyer measured by these authors (2773.5 mm) (Yamamoto et al., 2005) is also in line with classical anatomical descriptions (Ebeling and Reulen, 1988).
Functional MR imaging
fMRI involves the application of MR techniques for high-resolution (spatial and temporal) investigations of brain physiology. Local changes in cerebral hemodynamics are closely linked to local cerebral activity, and they can be assessed with the technique known as blood oxygen level–dependent (BOLD) fMRI. The BOLD contrast effect depends on changes in the deoxyhemoglobin content of blood during states of increased neuronal activity (Ogawa et al., 1990). Many studies have been performed to assess BOLD signal changes in normal humans under different conditions, e.g., during sensory stimulation or
motor and cognitive activities (Bandettini et al., 1992).
fMRI has now become the technology of choice for many functional activation studies in humans. Its advantages include the possibility to collect anatomic and functional data in a single session, noninvasiveness and lack of exposure to ionizing radiation (which make it suitable for repeated assessments of both patients and volunteers), and high availability (in most medical centers with clinical MR imaging services) (Kollias, 2004). Because visual stimulation is associated with robust changes in signal intensity, fMRI is particularly useful for studying visual function under physiological and pathological conditions.
Activation of the primary visual cortex can be easily demonstrated with BOLD fMRI during experiments involving the delivery of various visual stimuli (Fig. 10). The signals obtained are related to actual changes in visual neuronal activity, as demonstrated by Logothetis et al. (2001). These authors analyzed fMRI signals in light of simultaneously recorded electrical activity in the neurons of the primary visual cortex of
174
Fig. 10. Functional magnetic resonance imaging (fMRI) results of a single subject following visual task performance.
monkeys exposed to visual stimulation. In accordance with the results of previous studies (Bandettini et al., 1992; Kollias et al., 2000), their findings confirmed that localized increases in BOLD contrast reflect stimulus-evoked increases in neural activity. The response to a visual stimulus begins within a few hundred milliseconds of neuronal stimulation. The decrease in signal intensity observed 0.5–2.0 s after stimulus onset has been attributed to an early focal deoxygenation phase, which precedes increases in oxygenated hemoglobin caused by local enhancement of blood flow (Ernst and Hennig, 1994).
Direct relations between stimulus intensity and occipital responses have also been reported. Alvarez-Linera Prado et al. (2007) demonstrated correlation between the BOLD response and visual-stimulus intensity and found that cortical reactivity to these stimuli (especially those within the low-to-medium-intensity range) is higher in patients with photophobia than normal controls.
fMRI was first employed to establish the extent of striate and extrastriate cortical areas and to map the retinotopic borders of the visual cortex (Courtney and Ungerleider, 1997; Engel et al., 1997). Precise retinotopic mapping was impossible prior to the mid 1990s, when Engel et al. (1997) developed the technique of phase-encoded retinal stimulation. They used a contrast-reversing
checkerboard (contrast reversal rate, 8 Hz) presented at the center of gaze to create a strong neural response within area V1 of the human visual cortex. Subjects were exposed to expandingring and contracting-ring stimuli, which generated a traveling wave of neural activity within visual cortex. With this new approach, the investigators were able to distinguish the cortical representation of the fovea in the posterior cortex from that of the peripheral retina.
Many efforts were made to correlate neurological deficits with damage to specific brain areas. The first attempts to identify the anatomic sources of specific cerebral functions were based on the study of correlations between loss of function and brain lesion location. The early studies of visual impairments produced by focal lesions suggested that the human visual cortex is organized into two anatomically and functionally distinct units, the ventral and the dorsal pathways. Symptoms like visual object agnosia, prosopagnosia, and achromatopsia are produced by occipitotemporal lesions involving the ventral pathway, whereas optic ataxia, visual neglect, constructional apraxia, gaze apraxia, akinotopsia, and disorders of spatial cognition are the result of occipitoparietal lesions within the dorsal pathway (Boller and Grafman, 1989; Laskowitz et al., 1998).
Anatomical neuroimaging may not be sufficient to determine the extent of brain damage caused by cerebrovascular lesions, neoplasms, inflammatory states, or congenital disease. Many studies have demonstrated good agreement between fMRI findings and the results of traditional visual examinations. Patients with congruous homonymous hemianopia caused by retrochiasmatic lesions (Miki et al., 1996a) and those with visual field defects caused by prechiasmatic and chiasmatic lesions (Miki et al., 1996b) showed abnormal cortical activation that was concordant with the visual defect. fMRI thus appears to be a potentially valuable tool for assessing local brain function in patients with visual deficits.
In patients with space-occupying lesions involving the optic radiation, fMRI examinations revealed activation patterns in the visual cortex that were consistent with the patients’ visual field deficits and with traditional retinotopic representations.
Optic neuritis is a common manifestation of multiple sclerosis, a disease characterized by the development of multifocal, inflammatory, demyelinating lesions of the white matter. In patients with unilateral optic neuritis, fMRI has revealed that the response to visual stimuli of the affected eye is characterized by reductions in the area of activation in the primary visual cortex and by significant increases in the latency of the major positive component of the visual-evoked potential (VEP). fMRI can thus be considered a reliable method for obtaining detailed topographic information related to functional deficits in multiple sclerosis (Gareau et al., 1999).
fMRI can also be used to identify epileptogenic foci in patients with epilepsy based on the demonstration of abnormal activation patterns that are concordant with seizure onset and interictal epileptiform discharges; these studies showed agreement between fMRI data and EEG (Lengler et al., 2007).
Dyslexia is a developmental disorder characterized by low reading achievement in individuals whose cognitive abilities, motivation, and education are adequate for accurate, fluent reading. fMRI studies of subjects with dyslexia frequently exhibit hypoactivation in the left parietotemporal cortex together with hyperactivation in the left inferior frontal cortex. Hoeft et al. (2007) recently reported that the areas of hyperactivation reflected processes related to the subject’s current level of reading ability, independent of the dyslexia, whereas the areas of hypoactivation seen in the left parietotemporal and occipitotemporal lobes represent functional atypicalities related to the dyslexia itself.
In schizophrenics who experience visual hallucinations, fMRI has revealed increased cerebral activity in the ventral extrastriate visual cortex and in the hippocampus (Oertel et al., 2007).
Miki et al. (1996b) performed fMRI during monocular visual stimulation in patients with visual field losses caused by lesions of the optic nerve and chiasm, and the results showed agreement with the pattern of visual field defects. In patients with unilateral optic neuropathy, like that frequently seen in glaucoma, stimulation of the affected eye failed to activate the portion of the
175
primary visual cortex corresponding to the central visual field defects and reduced activity in the associated visual cortex. Patients with chiasmal compression, monocular stimulation caused markedly asymmetrical activation of the primary visual cortex, which corresponded to the visual field abnormality.
Recently, Duncan et al. (2007) demonstrated correlation between functional organization of the visual cortex (V1) and visual field deficits in patients with primary open-angle glaucoma (POAG). A retinotopic map of visual space was obtained for visual areas in occipital cortex. Templates were used to project regions within the visual field onto a flattened representation of cortex. The resulting BOLD fMRI response was compared to interocular differences in thresholds for corresponding regions of the visual field. The spatial pattern of activity observed in the flattened representation was consistent with the pattern of visual field loss. In patients withPOAG, the BOLD signal in human visual cortex is altered in a manner that is consistent with the loss of visual function, suggesting that fMRI can be used to quantify functional changes in glaucoma.
Proton MR spectroscopy
MR spectroscopy is a noninvasive tool for investigating the chemical environment of the brain. The proton MR spectrum is characterized by at least three peaks, which represent (1) the compounds creatine and phosphocreatine (Cr), which are generally associated with cellular energy metabolism; (2) choline (Cho), which is associated with cell membrane synthesis; and (3) N-acetyl aspartate (NAA), a marker of neuronal integrity. Several studies have demonstrated the usefulness of MR spectroscopy in clinical settings, for the study of seizure foci and neoplasms and for distinguishing recurrent tumor from radiation necrosis, metabolic diseases, and white-matter disease (Branda˜o and Domingues, 2004).
In a recent study, Boucard et al. (2007) performed proton MR spectroscopy with a singlevoxel technique in patients with glaucoma. They found that absolute levels of NAA in the occipital
176
brain of subjects with progressive visual field defects caused by age-related macular degeneration or glaucoma were not significantly different from those found in a group of control subjects. Visual field degeneration in both these diseases progresses slowly, and the authors hypothesized the rate of progression might not be high enough to provoke a decrease in NAA concentration. An alternative explanation is that the cortical area corresponding to the affected retinal region is too small to provoke changes in the NAA concentration that are detectable with proton MR spectroscopy (Boucard et al., 2007).
References
Alvarez-Linera Prado, J., Rı´os-Lago, M., Martı´n-Alvarez, H., Herna´ndez-Tamames, J.A., Escribano-Vera, J. and Sa´nchezdelRı´o, M. (2007) Functional magnetic resonance imaging of the visual cortex: relation between stimulus intensity and bold response. Rev. Neurol., 45(3): 147–151.
Artes, P.H. and Chauhan, B.C. (2005) Longitudinal changes in the visual field and optic disc in glaucoma. Prog. Retin. Eye Res., 24: 333–354.
Bandettini, P.A., Wong, E.C., Hinks, R.S., Tikofsky, R.S. and Hyde, J.S. (1992) Time course EPI of human brain function during task activation. Magn. Reson. Med., 25(2): 390–397.
Basser, P.J. (1995) Inferring microstructural features and the physiological state of tissues from diffusion-weighted images. NMR Biomed., 8(7–8): 333–344.
Basser, P.J. and Pierpaoli, C. (1996) Microstructural and physiological features of tissues elucidated by quantitative- diffusion-tensor. J. Magn. Reson. B, 111(13): 209–219.
Boller, F. and Grafman, J. (1989) Disorders of visual behavior. In: Goodglass H. and Damasio A.R. (Eds.), Handbook of Neuropsychology, Vol. 2. Elsevier, Amsterdam, pp 333–356.
Boucard, C.C., Hoogduin, J.M., van der Grond, J. and Cornelissen, F.W. (2007) Occipital proton magnetic resonance spectroscopy (1H-MRS) reveals normal metabolite concentrations in retinal visual field defects. PLoS ONE, 2(2): p. e222.
Branda˜o, L.A. and Domingues, R.C. (2004) MR Spectroscopy of the Brain. Lippincott Williams & Wilkins, Philadelphia.
Conturo, T.E., Lori, N.F., Cull, T.S., Akbudak, E., Snyder, A.Z., Shimony, J.S., McKinstry, R.C., Burton, H. and Raichle, M.E. (1999) Tracking neuronal fiber pathways in the living human brain. Proc. Natl. Acad. Sci. U.S.A., 96(18): 10422–10427.
Courtney, S.M. and Ungerleider, L.G. (1997) What fMRI has taught us about human vision. Curr. Opin. Neurobiol., 7(4): 554–561.
Dong, Q., Welsh, R.C., Chenevert, T.L., Carlos, R.C., MalySundgren, P., Gomez-Hassan, D.M. and Mukherji, S.K. (2004) Clinical applications of diffusion tensor imaging. J. Magn. Reson. Imaging, 19(1): 6–18.
Duncan, R.O., Sample, P.A., Weinreb, R.N., Bowd, C. and Zangwill, L.M. (2007) Retinotopic organization of primary visual cortex in glaucoma: comparing fMRI measurements of cortical function with visual field loss. Prog. Retin. Eye Res., 26(1): 38–56.
Ebeling, U. and Reulen, H-J. (1988) Neurosurgical topography of the optic radiation in the temporal lobe. Acta Neurochir. (Wien.), 92: 29–36.
Engel, S.A., Glover, G.H. and Wandell, B.A. (1997) Retinotopic organization in human visual cortex and the spatial precision of functional MRI. Cereb. Cortex, 7(2): 181–192.
Ernst, T. and Hennig, J. (1994) Observation of a fast response in functional MR. Magn. Reson. Med., 32(1): 146–149.
Filippi, M. and Inglese, M. (2001) Overview of diffusionweighted magnetic resonance studies in multiple sclerosis. J. Neurol. Sci., 186(1): S37–S43.
Gareau, P.J., Gati, J.S., Menon, R.S., Lee, D., Rice, G., Mitchell, J.R., Mandelfino, P. and Karlik, S.J. (1999) Reduced visual evoked responses in multiple sclerosis patients with optic neuritis: comparison of functional magnetic resonance imaging and visual evoked potentials. Mult. Scler., 5(3): 161–164.
Hajnal, J.V., Doran, M., Hall, A.S., Collins, A.G., Oatridge, A., Pennock, J.M., Young, I.R. and Bydder, G.M. (1991) MR imaging of anisotropically restricted diffusion of water in the nervous system: technical, anatomic, and pathologic considerations. J. Comput. Assist. Tomogr., 15(1): 1–8.
Hickman, S.J., Wheeler-Kingshott, C.A.M., Jones, S.J., Miszkiel, K.A., Barker, G.J., Plant, G.T. and Miller, D.H. (2005) Optic nerve diffusion measurement from diffusionweighted imaging in optic neuritis. AJNR Am. J. Neuroradiol., 26(4): 951–956.
Hoeft, F., Meyler, A., Hernandez, A., Juel, C., Taylor-Hill, H., Martindale, J.L., McMillon, G., Kolchugina, G., Black, J.M., Faizi, A., Deutsch, G.K., Siok, W.T., Reiss, A.L., Whitfield-Gabrieli, S. and Gabrieli, J.D. (2007) Functional and morphometric brain dissociation between dyslexia and reading ability. Proc. Natl. Acad. Sci. U.S.A., 104(10): 4234–4239.
Hoyt, W.F. and Luis, O. (1962) Visual fiber anatomy in the infrageniculate pathway of the primate. Arch. Ophthalmol., 68: 94–106.
Hui, E.S., Fu, Q.L., So, K.F. and Wu, E.X. (2007) Diffusion tensor MR study of optic nerve degeneration in glaucoma. Conf. Proc. IEEE Eng. Med. Biol. Soc., 2007: 4312–4315.
Jacobs, D.A. and Galetta, S.L. (2007) Neuro-ophthalmology for neuroradiologists. AJNR Am. J. Neuroradiol., 28(1): 3–8.
Kollias, S.S. (2004) Investigations of the human visual system using functional magnetic resonance imaging (FMRI). Eur. J. Radiol., 49(1): 64–75.
Kollias, S.S., Golay, X., Boesiger, P. and Valavanis, A. (2000) Dynamic characteristics of oxygenation-sensitive MR
signal during application of varying temporal protocols for imaging of human brain activity. Neuroradiology, 42(8): 591–601.
Laskowitz, D., Liu, G.T. and Galetta, S.L. (1998) Acute visual loss and other disorders of the eyes. Neurol. Clin., 16(2): 323–353.
Le Bihan, D. (1995) Molecular diffusion, tissue microdynamics and microstructure. NMR Biomed., 8: 375–386.
Lengler, U., Kafadar, I., Neubauer, B.A. and Krakow, K. (2007) fMRI correlates of interictal epileptic activity in patients with idiopathic benign focal epilepsy of childhood. A simultaneous EEG-functional MRI study. Epilepsy Res., 75(1): 29–38.
Logothetis, N.K., Pauls, J., Augath, M., Trinath, T. and Oeltermann, A. (2001) Neurophysiological investigation of the basis of the fMRI signal. Nature, 412(6843): 150–157.
Masutani, Y., Aoki, S., Abe, O., Hayashi, N. and Otomo, K. (2003) MR diffusion tensor imaging: recent advance and new techniques for diffusion tensor visualization. Eur. J. Radiol., 46(1): 53–66.
Miki, A., Nakajima, T., Fujita, M., Takagi, M. and Abe, H. (1996a) Functional magnetic resonance imaging in homonymous hemianopsia. Am. J. Ophthalmol., 121(3): 258–266.
Miki, A., Nakajima, T., Takagi, M., Shirakashi, M. and Abe, H. (1996b) Detection of visual dysfunction in optic atrophy by functional magnetic resonance imaging during monocular visual stimulation. Am. J. Ophthalmol., 122(3): 404–415.
Mori, S., Crain, B.J., Chacko, V.P. and van Zijl, P.C. (1999) Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann. Neurol., 45(2): 265–269.
Mori, S. and van Zijl, P.C. (2002) Fiber tracking: principles and strategies — a technical review. NMR Biomed., 15(7–8): 468–480.
Moseley, M.E., Cohen, Y., Kucharczyk, J., Mintorovitch, J., Asgari, H.S., Wendland, M.F., Tsuruda, J. and Norman, D. (1990) Diffusion-weighted MR imaging of anisotropic water diffusion in cat central nervous system. Radiology, 176(2): 439–445.
177
Nickells, R.W. (1996) Retinal ganglion cell death in glaucoma: the how, the why, and the maybe. J. Glaucoma, 5(5): 345–356.
Oertel, V., Rotarska-Jagiela, A., vandeVen, V.G., Haenschel, C., Maurer, K. and Linden, D.E. (2007) Visual hallucinations in schizophrenia investigated with functional magnetic resonance imaging. Psychiatry Res., 15(3): 269–273.
Ogawa, S., Lee, T.M., Kay, A.R. and Tank, D.W. (1990) Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc. Natl. Acad. Sci. U.S.A., 87: 9868–9872.
Pipe, J.G., Farthing, V.G. and Forbes, K.P. (2002) Multishot diffusion weighted FSE using PROPELLER MRI. Magn. Reson. Med., 47(1): 42–52.
Trip, S.A., Wheeler-Kingshott, C., Jones, S.J., Li, W.Y., Barker, G.J., Thompson, A.J., Plant, G.T. and Miller, D.H. (2006) Optic nerve diffusion tensor imaging in optic neuritis. Neuroimage, 30(2): 498–505.
Ueki, S., Fujii, Y., Matsuzawa, H., Takagi, M., Abe, H., Kwee, I.L. and Nakada, T. (2006) Assessment of axonal degeneration along the human visual pathway using diffusion trace analysis. Am. J. Ophthalmol., 142(4): 591–596.
Werring, D.J., Clark, C.A., Barker, G.J., Thompson, A.J. and Miller, D.H. (1999) Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology, 52(8): 1626–1632.
Wu, Q., Butzkueven, H., Gresle, M., Kirchhoff, F., Friedhuber, A., Yang, Q., Wang, H., Fang, K., Lei, H., Egan, G.F. and Kilpatrick, T.J. (2007) MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve. Neuroimage, 37(4): 1138–1147.
Yamamoto, A., Miki, Y., Urayama, S., Fushimi, Y., Okada, T., Hanakawa, T., Fukuyama, H. and Togashi, K. (2007) Diffusion tensor fiber tractography of the optic radiation: analysis with 6-, 12-, 40-, and 81-directional motion-probing gradients, a preliminary study. AJNR Am. J. Neuroradiol., 28(1): 92–96.
Yamamoto, T., Yamada, K., Nishimura, T. and Kinoshita, S. (2005) Tractography to depict three layers of visual field trajectories to the calcarine gyri. Am. J. Ophthalmol., 140(5): 781–785.
